<DOC>
	<DOCNO>NCT02082054</DOCNO>
	<brief_summary>This active v active comparative trial evaluate safety efficacy incremental dos atropine combination pseudoephedrine 120 mg/chlorpheniramine 8 mg adult patient history seasonal allergic rhinitis . Hypotheses define total nasal symptom score ( TNSS ) record subject diary efficacy establish statistical significance p &lt; 0.05 .</brief_summary>
	<brief_title>StahistRx Phase 2 , Five-arm , Parallel Group , Active v Active , Double-blind Study</brief_title>
	<detailed_description>Actives five study arm : Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.36 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.24 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.12 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg Atropine 0.24 mg</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<criteria>1 . Male female ethnic group 12 60 year age . 2 . History moderate severe SAR least two year ; define score 2 03 point scale 3 . Documentation sensitivity obtain medical record positive skin test vitro specific IgE test . 4 . Have TNSS score 6 least average 2.0 rhinorrhea subscore placeborun phase . 5 . Is nonpregnant , nonlactating female postmenopausal , naturally surgically sterile , agree use effective contraceptive method throughout course study . 6 . If female childbearing potential , must agree use list acceptable birth control method ... 7 . If female childbearing potential , negative urine human chorionic gonadotropin ( hCG ) pregnancy test screen 8 . Is able swallow whole tablet orally administer medication 9 . Is able understand provide sign informed consent 1 . Has asthma require corticosteroid treatment 2 . Is currently undergo chronic intermittent use inhale , oral , intramuscular , intravenous , and/or potent super potent topical corticosteroid 3 . Has take follow medication indicated time period prior study enrolment : Intranasal , opthalmic , systemic corticosteroid ( 1 month ) Intranasal cromolyn ( 2 week ) Intranasal systemic decongestant ( 3 day ) Intranasal systemic antihistamine ( 7 day ) leukotriene inhibitor ( 7 day ) 4 . Documented evidence acute significant chronic sinusitis , determine individual investigator 5 . Has history allergic reaction know sensitivity active inactive ingredient investigational product use study 6 . Chronic use concomitant medication ( e.g. , tricyclic antidepressant ) would affect assessment effectiveness study medication 7 . Rhinitis medicamentosa 8 . A history glaucoma 9 . Has know suspect pregnancy , plan pregnancy , lactation ( female patient ) 10 . Is currently receive immunotherapy , unless stable maintenance dose least 1 month . 11 . Presence medical condition might interfere treatment evaluation require change therapy . 12 . Plans travel outside study area substantial portion study period 13 . Has history last 2 year current evidence abuse illicit drug , prescription medication , alcohol , opinion Investigator , would interfere adherence study requirement . 14 . Has exposure investigational agent within 30 day prior study entry . 15 . Has clinically significant mental illness ( determined Investigator ) 16 . Has condition Investigator believe would interfere ability provide inform consent comply study instruction , might confound interpretation study result put patient undue risk</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>rhinitis</keyword>
	<keyword>seasonal</keyword>
	<keyword>allergic</keyword>
</DOC>